Association between the ERCC1 polymorphism and platinum-based chemotherapy effectiveness in ovarian cancer: a meta-analysis

Table 1 Characteristics of the Studies Included in the Analysis

Authors	Year of publication	Host ethnicity	Age (years Mean ± SD)		Samples (n)		Regimen of chemotherapy	Genotyping method
Authors	Year of publication	Host ethnicity	Resistant	Responder	Resistant	Responder	Regimen of chemotherapy	Genotyping method
Sokbom K. et al. [18]	2009	Asian	No data	No data	20	40	Atinum-Taxane	PCR-RFLP
Steffensen K.D. et al. [20]	2011	Caucasian	54.92 ± 11.42	52.33 ± 10.75	155	144	Carboplatin and Paclitaxel	PCR-DNA chip
Smith S. et al. [16]	2007	Caucasian	66.9 ± 7.8	68.33 ± 9.5	48	128	carboplatin or cisplatin and paclitaxel	PCR-RFLP
Qi B. et al. [11]	2013	Asian	No data	No data	73	147	Platium- Based, did not provide specific information	PCR-RFLP
Bösmüller H. et al. [19]	2011	Caucasian	59.7 ± 18.3	62.33 ± 13.5	14	27	Carboplatin-Taxane	PCR-RFLP
Steffensen K.D. et al. [17]	2008	Caucasian	61.1 ± 20	68.4 ± 14.7	12	88	Platium- Based, did not provide specific information	PCR-DNA chip
Moxley K.M. et al. [10]	2013	Caucasian	64.89 ± 13.2	71.28 ± 12.9	32	32	Platium- Based Chemotherapy	PCR-RFLP
Yang S. [21]	2011	Asian	76.9 ± 17.6	72.9 ± 15.9	71	138	Cisplatin or Carboplatin and cyclophosphamide	PCR-RFLP

PCR polymerase chain reaction, RFLP restriction fragment length polymorphism

ISSN: 1472-6874